• Please log in or register to access this feature.

Original Article

Predicting survival of patients with hypocellular myelodysplastic syndrome†

Development of a disease-specific prognostic score system

  1. Wei-Gang Tong MD1,
  2. Alfonso Quintás-Cardama MD1,
  3. Tapan Kadia MD1,
  4. Gautam Borthakur MD1,
  5. Elias Jabbour MD1,
  6. Farhad Ravandi MD1,
  7. Stefan Faderl MD1,
  8. William Wierda MD1,
  9. Sherry Pierce MD1,
  10. Jianqin Shan MD1,
  11. Carlos Bueso-Ramos MD2,
  12. Hagop Kantarjian MD1,
  13. Guillermo Garcia-Manero MD1,‡,*

Article first published online: 17 JAN 2012

DOI: 10.1002/cncr.27420

Issue

Cancer

Cancer

Volume 118, Issue 18, pages 4462–4470, 15 September 2012

Additional Information

How to Cite

Tong, W.-G., Quintás-Cardama, A., Kadia, T., Borthakur, G., Jabbour, E., Ravandi, F., Faderl, S., Wierda, W., Pierce, S., Shan, J., Bueso-Ramos, C., Kantarjian, H. and Garcia-Manero, G. (2012), Predicting survival of patients with hypocellular myelodysplastic syndrome. Cancer, 118: 4462–4470. doi: 10.1002/cncr.27420

Author Information

  1. 1

    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

  1. ‡

    Fax: (713) 794-4297

*Department of Leukemia, The University of Texas MD Anderson Cancer Center, Box 428, Houston, TX 77030

  1. †

    W.-G.T. and A.Q.-C. wrote the paper and analyzed the data. T.K., G.B., E.J., F.R., S.F., W.W., and H.K. contributed patients, helped write the paper, and analyzed the data. S.P. and J.S. performed part of the statistical analysis and helped write the paper. C.B.-R. was the hematopathologist who reviewed cases. G.G.-M. designed the study, analyzed data, contributed patients, and wrote the paper.

  2. ‡

    Fax: (713) 794-4297

Publication History

  1. Issue published online: 5 SEP 2012
  2. Article first published online: 17 JAN 2012
  3. Manuscript Accepted: 8 NOV 2011
  4. Manuscript Revised: 21 SEP 2011
  5. Manuscript Received: 14 JUL 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (410K)

Keywords:

  • hypocellular;
  • myelodysplastic syndrome;
  • prognostic score;
  • International Prognostic Scoring System

Abstract

BACKGROUND:

Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow. Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS.

METHODS:

The authors studied a cohort of 253 patients with hypocellular MDS diagnosed at The University of Texas MD Anderson Cancer Center between 1993 and 2007 and a cohort of 1725 patients with hyper-/normocellular MDS diagnosed during the same time period.

RESULTS:

Patients with hypocellular MDS presented more frequently with thrombocytopenia (P < .019), neutropenia (P < .001), low serum β-2 microglobulin (P < .001), increased transfusion dependency (P < .001), and intermediate-2/high-risk disease (57% vs 42%, P = .02) compared with patients with hyper-/normocellular MDS. However, no difference in overall survival was observed between the 2 groups (P = .28). Multivariate analysis identified poor performance status (Eastern Cooperative Oncology Group ≥2), low hemoglobin (<10 g/dL), unfavorable cytogenetics (−7/7q or complex), increased bone marrow blasts (≥5%), and high serum lactate dehydrogenase (>600 IU/L) as adverse independent factors for survival.

CONCLUSIONS:

A new prognostic model based on these factors was built that segregated patients into 3 distinct risk categories independent of International Prognostic Scoring System (IPSS) score. This model is independent from the IPSS, further refines IPSS-based prognostication, and may be used to develop of risk-adapted therapeutic approaches for patients with hypocellular MDS. Cancer 2012. © 2012 American Cancer Society.

View Full Article (HTML) Get PDF (410K)